Status:
COMPLETED
Treatment With Elexacaftor/Tezacaftor/Ivacaftor, in Patients With Cystic Fibrosis and Caloric Intake
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
2-100 years
Brief Summary
The aim of the study is to describe the evolution of caloric intake in patients with cystic fibrosis with an indication to start treatment with Elexacaftor/Tezacaftor/Ivacaftor according to the Market...
Detailed Description
Cystic fibrosis is a genetic pathology linked to a dysfunction of the CFTR protein. Undernutrition is common in the natural course of cystic fibrosis, it is linked to exocrine pancreatic insufficienc...
Eligibility Criteria
Inclusion
- Patient with cystic fibrosis
- Patient with an indication to start treatment with Elexacaftor/Tezacaftor/Ivacaftor according to the Marketing Authorization.
- Patient who has not received treatment with CFTR modulators in the 6 months preceding inclusion.
- No opposition expressed by the patient (if ≥ 18 years) or by at least one of the holders of parental authority and the child (if \< 18 years).
- Be affiliated to a social security scheme or be a beneficiary of such a scheme.
Exclusion
- \-
Key Trial Info
Start Date :
October 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06072365
Start Date
October 21 2021
End Date
January 15 2023
Last Update
October 10 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
UHBordeaux
Bordeaux, France, 33404
2
UHLimoges
Limoges, France, 87042
3
UHToulouse
Toulouse, France, 31059